79 results
DEFA14A
ZVRA
Zevra Therapeutics Inc
29 Apr 24
Additional proxy soliciting materials
7:49am
point of value creation.
We’re Committed to Governance Best Practices
From the beginning of 2023 through today, the composition of our Board … .
The newly composed Board immediately moved into action by affirming its commitment to employing governance best practices for a company of our size and stage
424B3
yg1i1o64up
10 Oct 23
Prospectus supplement
5:07pm
S-4/A
3lo fxhnfb9t
6 Oct 23
Registration of securities issued in business combination transactions (amended)
4:06pm
S-4
b8pui8xmni6l
28 Sep 23
Registration of securities issued in business combination transactions
9:25pm
425
i4zvp
31 Aug 23
Business combination disclosure
8:03am
8-K
EX-2.1
iwhi5jafua9m um0ao
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
424B3
54zb3vm0j otpmews
10 Nov 21
Prospectus supplement
5:19pm
424B3
d96y5olk0d0x68t
19 Oct 21
Prospectus supplement
9:27am
8-K
EX-99.1
7zvg7xjzfs0
19 Oct 21
KemPharm, Inc. Announces Uplisting to The Nasdaq Global Select Market
9:24am